Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia.
Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
Int Forum Allergy Rhinol. 2018 Apr;8(4):461-470. doi: 10.1002/alr.22093. Epub 2018 Feb 2.
Persistent mucosal inflammation in patients with chronic rhinosinusitis (CRS) often results in ongoing symptoms, recurrence of polypoid mucosa, infective exacerbations, and further systemic medication despite surgical intervention. Debate exists as to the most effective topical therapy in CRS.
The objective was to determine if corticosteroid delivered via a nasal irrigation or via a simple nasal spray would be more effective in controlling the symptoms and signs of CRS. A double-blind placebo-controlled randomized trial over 12 months was performed between 3 tertiary rhinologic clinics. After sinus surgery, all patients performed a nasal irrigation followed by a nasal spray once a day for 12 months. Groups were defined by corticosteroid (2 mg mometasone) delivered by either spray or irrigation. The primary outcomes were patient-reported symptoms: visual analogue score (VAS) and 22-item Sino-Nasal Outcome Test (SNOT-22), a global rating of sinonasal function. Secondary outcomes were also recorded from radiology (Lund-Mackay score [LMS]) and endoscopic (Modified Lund-Kennedy score [mLKS]) assessments.
A total of 44 patients were randomized (age 50.3 ± 13.0 years; 40.9% female). Overall, patients improved significantly from either intervention. However, the corticosteroid nasal irrigation group had greater improvement in nasal blockage (-69.91 ± 29.37 vs -36.12 ± 42.94; p = 0.029), a greater improvement on LMS (-12.07 ± 4.43 vs -7.39 ± 6.94; p = 0.031) and less inflammation on mLKS at 12 months (7.33 ± 11.55 vs 21.78 ± 23.37; p = 0.018). One-year posttreatment blockage, drainage, fever, and total VAS scores were all lower in the corticosteroid irrigation group.
In the setting of diffuse or patchy CRS disease, the use of corticosteroid delivered by nasal irrigation is superior to simple nasal spray in postsurgical patients.
慢性鼻-鼻窦炎(CRS)患者的持续性黏膜炎症常导致持续存在的症状、息肉样黏膜的复发、感染性加重以及尽管进行了手术干预但仍需进一步全身药物治疗。目前仍存在关于 CRS 最有效局部治疗的争议。
本研究旨在确定通过鼻腔冲洗或简单的鼻腔喷雾给予皮质类固醇在控制 CRS 症状和体征方面是否更有效。在 3 家三级鼻科诊所进行了为期 12 个月的双盲安慰剂对照随机试验。鼻窦手术后,所有患者均接受鼻腔冲洗,然后每天接受一次鼻腔喷雾治疗,共 12 个月。通过喷雾或冲洗给予皮质类固醇(2 mg 糠酸莫米松)来定义组。主要结局是患者报告的症状:视觉模拟评分(VAS)和 22 项鼻-鼻窦结局测试(SNOT-22)、鼻-鼻窦功能的总体评分。还从放射学(Lund-Mackay 评分[LMS])和内镜(改良 Lund-Kennedy 评分[mLKS])评估中记录次要结局。
共纳入 44 例患者(年龄 50.3 ± 13.0 岁;40.9%为女性)。总体而言,患者在任何干预措施后均有显著改善。然而,皮质类固醇鼻腔冲洗组在鼻塞方面的改善更大(-69.91 ± 29.37 对-36.12 ± 42.94;p = 0.029)、LMS 改善更大(-12.07 ± 4.43 对-7.39 ± 6.94;p = 0.031)和 12 个月时 mLKS 炎症更少(7.33 ± 11.55 对 21.78 ± 23.37;p = 0.018)。皮质类固醇鼻腔冲洗组治疗后 1 年鼻塞、引流、发热和总 VAS 评分均较低。
在弥漫性或斑片状 CRS 疾病的情况下,与简单的鼻腔喷雾相比,手术后患者使用鼻腔内皮质类固醇冲洗在术后患者中更有效。